Non-absorbable sugar based Lifespan extension therapy:  Lactulose (brand names: Cholac, Generlac, Consulose, Duphalac, others), a non-absorbable sugar aids in the treatment of constipation and hepatic encephalopathy,  increases life span via up-regulation of its target gene BubR1, 4/March/2018, 11.27 am

Activation of the PD-1 pathway for Pain therapy: DAMGO ([D-Ala2, N-MePhe4, Gly-ol]-enkephalin), a synthetic opioid peptide, increases the expression of PD-L1, attenuates acutes and chronic pain, and suppresses mechanical and thermal hypersensitivity and inhibits nociceptive neuron excitability via up-regulation of its target gene, 4/March/2017, 11.07 am
March 4, 2018
Amino acid-based therapy for TIIDM and obesity-associated metabolic deficits: Glycine, a non-essential amino acid and inhibitory neurotransmitter,  increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 4/March/2018, 11.45 am
March 4, 2018
Show all

 What they say: Introduction: 

A recent study from the Department of Genetics, Paul F. Glenn Laboratories for the Biological Mechanisms of Aging Harvard Medical School, Boston,USA; and Department of Pharmacology, School of Medicine, The University of New South Wales, Australia shows that Sirtuin-2 induces the checkpoint kinase BubR1 to increase lifespan. This study was published, in the 1 July  2014 issue of the journal  “EMBO”, by Prof Sinclair, North BJ, and others.


What we say: 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  Non-absorbable sugar based Lifespan extension therapy:  Lactulose (brand names: Cholac, Generlac, Consulose, Duphalac, others), a non-absorbable sugar aids in the treatment of constipation and hepatic encephalopathy,  increases life span via up-regulation of its target gene BubR1


From research findings to Therapeutic Opportunity: 

This study suggests, for the first time, that  Lactoloseby increasing the expression of its target gene, it may: (a) increase the expression of BuBR1; (b) decrease the expression of p70 S6 Kinase; and (c) regulate the expression of a number of longevity-promoting molecules (Fig. 1).

[easy_payment currency=”USD”]

Figure 1.  The Non-absorbable sugar Lactulose may extend  mammalian life span via up regulation of BuBR1 and down regulation of p70 S6 Kinase

Figure 2. The chemical structure of Lactulose.  Lactulose functions as a longevity-promoter through induction of BuBR1.

Thereby, it may: (1) increase insulin sensitivity; (2) attenuate cognitive impairment; (3) delay diseases of aging; (4) slow down cardiac aging; (5) promote resistance to bone, immune and motor dysfunction; (6) promote tissue rejuvenation; and (7) prolong median life span. Thus, pharmacological formulations encompassing “Lactolose  or its analogues, either alone or in combination with other drugs, may be used to extend the lifespan of an individual (fig. 2).


Details on the research findings: 

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Amount: $500#

Undisclosed mechanistic information: How Lactulose increases the expression of BubR1 and extends mammalian life-span

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

# Research cooperation


References

Web: http://genomediscovery.org or http://newbioideas.com

CitationBoominathan, L., Non-absorbable sugar based Lifespan extension therapy:  Lactulose (brand names: Cholac, Generlac, Consulose, Duphalac, others), a non-absorbable sugar aids in the treatment of constipation and hepatic encephalopathy,  increases life span via up-regulation of its target gene BubR1, 4/March/2018, 11.27 am,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at admin@genomediscovery.org

Comments are closed.